Novo Nordisk Cuts 9,000 Jobs and Slashes Guidance. Why the Stock Is Rising.

Core Insights - The weight-loss drugs giant has reduced its profit guidance for the second time in six weeks [1] Company Summary - The company is facing challenges that have led to a downward revision in profit expectations [1] Industry Summary - The weight-loss drug industry is experiencing volatility, impacting major players and their financial forecasts [1]